[1]吕建林 冉思邈 胡振斌 毛德文.海珠益肝化纤方治疗肝纤维化的临床疗效观察[J].大众科技,2018,20(11):29-31.
　The Clinical Observation of Haizhu Yigan Huaxian Docoction on Treating Liver Fibrosis[J].Popular Science & Technology,2018,20(11):29-31.
点击复制

海珠益肝化纤方治疗肝纤维化的临床疗效观察()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
20
期数:
2018年11期
页码:
29-31
栏目:
医药与卫生
出版日期:
2018-11-20

文章信息/Info

Title:
The Clinical Observation of Haizhu Yigan Huaxian Docoction on Treating Liver Fibrosis
作者:
吕建林1 冉思邈2 胡振斌1 毛德文1
（1.广西中医药大学第一附属医院，广西 南宁 5300231；2.广西中医药大学，广西 南宁 530023）
关键词:
海珠益肝化纤方; 肝纤维化; 临床疗效
Keywords:
Haizhu Yigan Huaxian Docoction;  liver fibrosis;  clinical efficacy
文献标志码:
A
摘要:
目的：观察海珠益肝化纤方治疗肝纤维化（肝胆湿热证）的临床疗效。方法：将符合诊断标准的80 例患者随机分为治疗组和对照组，治疗组使用海珠益肝化纤方治疗，对照组使用水飞蓟素片治疗。比较治疗前后临床症状、肝功能(AST、ALT、TBIL、A、A/G)、肝纤指标（PⅢP、CIV、LN、HA）、FIB-4 指数、肝脏硬度值的变化。结果：治疗组临床症状明显改善，与对照比较有显著差异（P＜0.05），治疗组与对照组治疗后AST、ALT、TBIL、A、A/G、PⅢP、CIV、LN、HA、FIB-4指数、肝脏硬度值均明显改善（P＜0.05），组间比较，治疗组AST、ALT、TBIL、A、A/G、PⅢP、CIV、LN、HA、FIB-4 指数、肝脏硬度值改善程度优于对照组（P＜0.05）。结论：海珠益肝化纤方治疗肝纤维化（肝胆湿热证）在改善症状、肝功能、肝纤指标、FIB-4 指数、肝脏硬度值方面均优于水飞蓟素片。
Abstract:
Objective: To observe the clinical efficacy of Haizhu Yigan Huaxian Docoction in treating liver fibrosis (hepatobiliary damp-heat syndrome). Methods: 80 patients who meet the diagnostic criteria were randomly divided into treatment group and control group. The treatment group was treated with Haizhu Yigan Huaxian Docoction, while the control group was treated with silymarin tablets. The changes of clinical symptoms, liver function (AST, ALT, TBIL, A, A/G), liver fibrosis index (PⅢP, CIV, LN, HA), FIB-4 index and liver hardness were compared before and after treatment. Results: The clinical symptoms in the treatment group were significantly improved compared with the control group (P＜0.05). After treatment, the AST, ALT, TBIL, A, A/G, PⅢP, CIV, LN, HA, FIB-4 of the two groups were all significantly improved (P＜0.05), and these indexes of the treatment group were better than that of the control group (P＜0.05).Conclusion: Haizhu Yigan Huaxian Docoction on treating liver fibrosis can in improving symptoms, liver function, liver fiber index, FIB-4 index and its clinical efficacy is better than that of silymarin tablets.

参考文献/References:

【参考文献】 [1] 肝纤维化诊断及疗效评估共识[J].药品评价,2007(4):265-266. [2] 肝纤维化中西医结合诊疗指南[J].中国中西医结合杂志, 2006(11):1052-1056. [3] 李隽,韩涛.2015 中国慢性乙型肝炎指南更新要点解析[J].临床荟萃, 2016, 31(7):701-704. [4] 肝脏硬度评估小组.瞬时弹性成像技术诊断肝纤维化专家意见[J].中华肝脏病杂志,2013(21):420-423. [5] 汪美凤,平键.肝星状细胞主要信号转导通路与肝纤维化的关系[J].实用肝脏病杂志,2010,13(6):466-469. [6] Hernandezgea V,Friedman S L.Pathogenesis of Liver Fibrosis [J].Annu Rev Pathol,2011,6(1):425-456. [7] Sohrabpour A A,Mohamadnejad M,Malekzadeh R.Review article:the reversibility of cirrhosis[J].Alimentary Pharmacology & Therapeutics,2012,36(9):824-832.

相似文献/References:

[1]唐梦华,吴玉强.治疗肝纤维化瑶药复方黄根方的研究进展[J].大众科技,2019,21(09):63.
　Research Progress of Cmpound HuangGen of Guangxi Yao Medicine in theTreatment of Hepatic Fibrosis[J].Popular Science & Technology,2019,21(11):63.
[2]杨寿松 张龄予 吕 超 刘辉华 陆石俊 覃武海 张荣臻.棒柄花叶清肝胶囊联合替诺福韦治疗慢性乙肝肝纤维化患者的疗效观察[J].大众科技,2022,24(06):124.
　Observation on the Curative Effect of Bangbing Huaye Qinggan Capsule Combined with Tenofovir in the Treatment of Chronic Hepatitis B Patients with Liver Fibrosis[J].Popular Science & Technology,2022,24(11):124.
[3]黎 妍 罗伟生.中医药防治肝纤维化的研究进展[J].大众科技,2018,20(09):52.
　Research Progress on Prevention and Treatment of Liver Fibrosis with Traditional Chinese Medicine[J].Popular Science & Technology,2018,20(11):52.
[4]王玉婷 梁诗雨 谢宇娟 李舒展 徐 怡 王佳慧 赵铁建 郑 洋.基于网络药理学研究扶正化瘀方抗肝纤维分子机制[J].大众科技,2022,24(08):59.
　Study on the Molecular Mechanism of Fuzheng Huayu Prescription Against Liver Fiber Based on Network Pharmacology[J].Popular Science & Technology,2022,24(11):59.
[5]唐 盼 李 媛.中药单药与细胞自噬关系影响肝纤维化研究[J].大众科技,2019,21(02):82.
　Study on the Effect of Chinese Medicine on Hepatic Fibrosis[J].Popular Science & Technology,2019,21(11):82.
[6]刘露露,潘子恒,彭 岳,等.TGF-β1/Smads 信号通路在肝纤维化中的调控作用概述[J].大众科技,2019,21(07):73.
　Overview of the Regulation of TGF-β1/Smads Signaling Pathway in Hepatic Fibrosis[J].Popular Science & Technology,2019,21(11):73.
[7]江家鹏,黄菊芳,张扬武.熊果酸抑制肝纤维化的研究进展[J].大众科技,2020,22(05):33.
　Research Progress of Ursolic Acid in Inhibiting Against Liver Fibrosis[J].Popular Science & Technology,2020,22(11):33.
[8]张艳培 梁 健 邓 鑫 梁明坤 张冰冰 徐粤娟.浅析肝纤维化发生机制[J].大众科技,2021,23(2):40.
[9]王梓塨 邱 华 朱玟霜 李 旺 蒙荫杰 王倩倩.细胞外囊泡在肝纤维化进展中的作用机制及临床意义[J].大众科技,2022,24(12):61.
　Mechanism and Clinical Significance of Extracellular Vesicles in the Progression of Hepatic Fibrosis[J].Popular Science & Technology,2022,24(11):61.
[10]郑博文 郑 洋 郭新华 梁馨云 吴日舟 任秋怡 赵铁建.外泌体调控肝纤维化的研究进展[J].大众科技,2022,24(11):68.
　Research Progress in the Regulation of Liver Fibrosis by Exosomes[J].Popular Science & Technology,2022,24(11):68.

备注/Memo

备注/Memo:
【收稿日期】2018-09-11 【基金项目】广西壮族自治区卫生和计划生育委员会基金课题“海珠益肝化纤方对大鼠肝组织α-SMA 和TGFβ1 表达影响的研究”（Z2015472）；国家中医药管理局慢性重型肝炎解毒化瘀重点研究室。 【作者简介】吕建林，男，广西中医药大学第一附属医院副主任医师，博士，研究方向为肝病。 【通信作者】毛德文，男，广西中医药大学第一附属医院主任医师，博士，研究方向为肝病。
更新日期/Last Update: 2018-12-19